Occupational exposure to graphene based nanomaterials: Risk assessment by Pelin, Marco et al.
Nanoscale
REVIEW
Cite this: Nanoscale, 2018, 10, 15894
Received 18th June 2018,
Accepted 12th July 2018
DOI: 10.1039/c8nr04950e
rsc.li/nanoscale
Occupational exposure to graphene based
nanomaterials: risk assessment
Marco Pelin, a Silvio Sosa, a Maurizio Prato *b,c,d and Aurelia Tubaro *a
Graphene-based materials (GBMs) are a family of novel materials including graphene, few layer graphene
(FLG), graphene oxide (GO), reduced graphene oxide (rGO) and graphene nanoplatelets (GNP). Currently,
the risk posed by them to human health is associated mainly with the occupational exposure during their
industrial and small-scale production or waste discharge. The most signiﬁcant occupational exposure
routes are inhalation, oral, cutaneous and ocular, inhalation being the majorly involved and most studied
one. This manuscript presents a critical up-to-date review of the available in vivo toxicity data of the most
signiﬁcant GBMs, after using these exposure routes. The few in vivo inhalation toxicity studies (limited to
5-days of repeated exposure and only one to 5 days per week for 4 weeks) indicate inﬂammatory/ﬁbrotic
eﬀects at the pulmonary level, not always reversible after 14/90 days. More limited in vivo data are avail-
able for the oral and ocular exposure routes, whereas the studies on cutaneous toxicity are at the initial
stage. A long persistence of GBMs in rodents is recorded, while contradictory genotoxic data are reported.
Data gap identiﬁcation is also provided. Based on the available data, the occupational exposure limit
cannot be determined. More experimental toxicity studies according to speciﬁc guidelines (tentatively
validated for nanomaterials) and more information on the actual occupational exposure level to GBMs are
needed. Furthermore, ADME (Absorption, Distribution, Metabolism, Excretion), genotoxicity, develop-
mental and reproductive toxicity data related to the occupational exposure to GBMs have to be
implemented. In addition, sub-chronic and/or chronic studies are still needed to completely exclude
other toxic eﬀects and/or carcinogenicity.
1. Introduction
In recent years, the development of carbon-based nano-
materials (CBNs) and nanotechnology has constantly
increased, oﬀering a wide range of novel opportunities and
solutions in diﬀerent areas of research and application,
which involve the environment, manufacturing technology
and health care. As a consequence, an emerging area of
concern in toxicology is represented by the manufactured
nanomaterials.1
One of the last discovered CBNs is graphene, consisting of
two-dimensional, single atom thick sheets of planar sp2 bound
carbons arranged in a honeycomb-like structure, with a high
surface area on both sides of the planar axis.2 Furthermore,
diﬀerent graphene-based materials (GBMs) have been obtained
by oxidation and/or functionalization of graphene, and
characterized by a variable lateral size, thickness, surface
area, shape, carbon-to-oxygen ratio and possible surface
functionalization.3–6 GBMs are promising tools for a broad
range of possible applications in electronics, energy techno-
logy, sensors and biomedicine.6,7 However, GBMs are sur-
rounded by a plethora of unanswered questions regarding
their safety. Although their potential toxicity has already been
highlighted, limited toxicity studies on GBMs are available and
the risk posed by them to human health remains largely
unexplored. In fact, despite more than 19 000 scientific
publications on GBMs are available since their discovery by
Novoselov et al.,8 only about 250 of them reported toxicity data
and about 70 (0.4% of total publications) included in vivo
toxicity findings on laboratory animals (Fig. 1), the key com-
ponent of the hazard identification process.
The main risk to human health posed by GBMs appears to
be associated with the occupational exposure to these
materials, their applications being still at the experimental
stage.5 During their industrial or small-scale production and
waste discharge, humans can be exposed to GBMs mainly by
inhalation, cutaneous and ocular routes, the respiratory tract,
the skin and the eyes being in direct contact with the work
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environment. Ingestion can also occur by accidental oral
intake and/or by secondary swallowing of inhaled GBMs.
In the occupational hazard assessment, various types of
data are used, including human data, data from laboratory
animal studies, data from in vitro studies and non-testing data
that can be derived from the physicochemical properties of a
substance. For GBMs, human data, case reports and medical
surveys of workers are not available so far. Thus, on the basis
of the occupational exposure routes, we carried out a critical
review of the literature on GBM toxicity provided by laboratory
animal studies, together with monitoring data in the work
environment. In vivo toxicity studies were focused on few layer
graphene (FLG), graphene oxide (GO), reduced graphene oxide
(rGO) and graphene nanoplatelets (GNP), which are considered
as starting materials for further functionalization and of inter-
est for industrial production.
2. Methods of literature review
A systematic review of the literature on GBM toxicity in labora-
tory mammals and monitoring data in occupational settings
was performed with no time restriction, according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines.9 The electronic databases
(PubMed, Scopus and ToxLine) were used as data sources,
using the term “graphene”.
Inclusion criteria were: (1) in vivo studies on FLG, GO, rGO
and GNP in laboratory mammals after exposure routes
mimicking possible occupational exposure in humans; (2)
monitoring data in the work environment; (3) full text articles;
(4) English language. Exclusion criteria included editorials,
not related abstracts and studies carried out on functionalized
and/or composite forms of graphene (i.e. polymer- or polysac-
charide-conjugated graphene). For each study, information
including the physicochemical properties of the administered
GBMs, dosage and routes of exposure as well as outcomes was
extracted independently.
3 In vivo toxicity studies related to
occupational exposure
As shown in Fig. 2, very few and incomplete data related to
GBM toxic eﬀects after the main occupational exposure routes
are available, so far.
Respiratory exposure
The majority of in vivo toxicity studies were carried out to
assess the eﬀects at the respiratory level after exposure to
GBMs by inhalation, intratracheal instillation or pharyngeal
aspiration. Studies in rodents after acute exposure to GBMs by
intratracheal instillation or pharyngeal aspiration revealed rela-
Fig. 1 Number of publications reporting toxicity studies of GBMs com-
pared with the total number of publications on graphene, for each year
(source: http://www.pubmed.com; keywords: graphene, in vivo toxicity
or in vitro toxicity).
Fig. 2 Summary of the existing knowledge on GBM toxicity in animal models. As signs of toxicity, data of inﬂammation, granuloma formation,
ﬁbrosis and necrosis reported in the revised literature were considered. Data are divided between the main occupational exposure routes. Pictures
report the organs in which the main toxic eﬀects (on the right) and biodistribution (on left) of the main GBMs (FLG, GO, rGO, GNP) were found.
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tively severe lung inflammation, as reported in a recent
review.10 Among the investigated GBMs, on evaluating inflam-
matory cells and/or inflammatory markers in the broncho-
alveolar lavage fluid as indices of lung inflammation, GO
appeared to be the most toxic one compared to rGO, GNP or
FLG, which appeared to be the least toxic GBM at the pulmon-
ary level.10–17 In contrast, in a very recent comparative study in
male C57BL/6 mice (8 weeks-old), pharyngeal aspiration of GO
induced lower toxic eﬀects than rGO.18 However, it should be
noted that the physicochemical properties of the tested
materials are not always completely reported in these studies
(Table 1), making a direct comparison of the eﬀects of GBMs
diﬃcult. For instance, chemical composition is not always
reported for GO and/or rGO, giving no information on the oxi-
dation state of these materials. Similarly, thickness, surface
area and chemical composition data are missing in the
majority of the studies.
The studies after intratracheal instillation also suggest that
the level of graphene dispersion seems to aﬀect its lung tox-
icity: highly dispersed graphene induced modest acute lung
inflammation without fibrosis in male C57BL/6 mice (8–12
week-old) and its toxicity appeared to be lower than that of
aggregated graphene, which lodged in the airways and
induced local fibrosis.11 Furthermore, graphene appears to be
accumulated mainly in the lungs, as recorded for 14C-FLG
(5 µg per mouse) in male ICR mice (4 weeks-old): 47% of the
dose was still detected in the lungs after 4 weeks and the
remaining was distributed in the liver and spleen.14 Similarly,
after intratracheal instillation, GNP (2.5–5.0 mg kg−1) was
retained in the lungs of male ICR mice (6 weeks-old) for up to
28 days.13 Very recently, a reproductive toxicity study was
carried out in male NMRI mice (age/weight not specified) after
the intratracheal instillation of commercial GO once a week for
7 consecutive weeks (18 µg per mouse per instillation; cumu-
lative dose: 126 µg per mouse). The increased neutrophil
number in the broncho-alveolar lavage fluid suggested pul-
monary inflammation.19
In conclusion, these few studies after intratracheal instilla-
tion suggest the lung as the target organ and the storage depot
of GBMs, with the following toxicity rank: FLG < GNP < rGO <
GO. Diﬀerent pieces of evidence of lung inflammation and
fibrosis were observed both after acute exposure and after one
exposure per week for 7 consecutive weeks. Moreover, a long
persistence of 14C-FLG and GNP in the lungs was observed.
However, intratracheal instillation or pharyngeal aspiration
involves a non-physiological delivery of GBMs, which may lead
to a less homogeneous distribution of materials as well as
higher local concentrations and toxic eﬀects than those
occurring by occupational inhalation exposure.10 For these
reasons, inhalation exposure by head–nose or only-nose
delivery systems, mimicking the usual human exposure
scenario, is more suitable for the hazard identification and
characterization.
Currently, only five in vivo studies after inhalation exposure
to FLG, GO or GNP are reported. Each study was carried out in
rats exposed to an atmosphere containing particles with an
aerodynamic diameter small enough to reach the broncho-
alveolar region (Table 2). The first study was carried out in
male Wistar rats (7 weeks-old) head–nose exposed for 5 days
(6 h per day) to FLG containing 3D-graphite impurities. The
atmosphere contained a mean concentration ranging from
0.54 to 10.1 mg m−3 with calculated particle depositions using
apparent and agglomerate densities of 0.26 and 0.29 mg per
lung. Three and 24 days after the last treatment, the broncho-
Table 1 Physicochemical properties of GBMs evaluated in the in vivo studies after other respiratory exposure (intratracheal exposure and
pharyngeal aspiration)
Lateral
size (nm)
Thickness
Surface area
Chemical
composition Impurity Density Aggregation
In vivo
exposure
route Ref.nm Layers
FLG 60–590 0.97–3.94 4–6 n/a C 89% n/a n/a Aggregated it 14
O 6%
N 3.6%
H 1.4%
n/a 1.2–5.0 n/a 40 000 nm2 n/a n/a n/a Aggregated it 11
5000–30 000 n/a 10 100 m2 g−1 n/a n/a 2 g cm−3 Aggregated pa 12
GO 2000–3000 2 2–3 338–441 m2 g−1 n/a n/a n/a n/a it 19
n/a 0.5–2.0 n/a 200 000 nm2 n/a n/a n/a n/a it 11
100–150 n/a n/a n/a n/a n/a n/a Aggregated pa 18
2000–3000 n/a 2–3 n/a n/a Inorganic
impurities (<1.5%)
n/a n/a it 16
rGO 100–150 n/a n/a n/a n/a n/a n/a Aggregated pa 18
1000–2000 n/a 2–3 411 m2 g−1 n/a Inorganic
impurities (<1.5%)
n/a n/a it 16
GNP 2000 3–4 n/a 735 m2 g−1 n/a n/a n/a n/a it 13
2000–20 000 8–25 28–84 106–747 m2 g−1 n/a n/a n/a Aggregated pa 15
<2000 <5 nm <4 >700 m2 g−1 n/a n/a n/a n/a it 17
it = intratracheal exposure; pa = pharyngeal aspiration. n/a = data not available.
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alveolar lavage fluid of rats exposed to 3.05 or 10.1 mg FLG per
cm2 showed cytological, cytokine and enzyme activity changes
related to acute/sub-acute inflammation. In parallel, a dose-
dependent accumulation of single macrophages or small
aggregates of alveolar macrophages loaded with black particles
(recognized as graphene) were found in the lungs of all FLG-
treated rats (mainly in the lumen of alveoli; only a few in the
alveolar wall, alveolar ducts and terminal bronchioles). In
addition, lung microgranulomas were also observed after the
recovery period of 24 days, without any alteration of the lung
parenchyma. For this study, the authors declared to have fol-
lowed the Organization for Economic Co-operation and
Development (OECD) test guideline (TG) 412, which indicates
a 4-week exposure period (5 days per week; 6 h day−1).
However, the rats were exposed to FLG only for 1 week (5 days;
6 h day−1).20
In another study, male Sprague-Dawley rats (6 weeks-old)
were nose-only exposed for 5 days (6 h day−1) to commercial
FLG. The mean atmosphere FLG concentrations were 0.68 or
3.86 mg m−3, corresponding to deposited doses of 3.6 or
20.3 μg per rat per day, respectively. The exposure to FLG did
not change the body weight or organ weight of the rats, also
during the recovery period of 28 days. No significant diﬀerence
was observed in the blood levels of lactate dehydrogenase,
protein and albumin between the FLG-treated rats and con-
trols. Histopathological analysis showed FLG ingestion by
alveolar macrophages.21
In a study on GNP, male Sprague-Dawley rats (6 weeks-old)
were nose-only exposed for 4 weeks (6 h day−1, 5 days per
week) to commercial GNP and monitored up to 90 days after
exposure, according to the OECD TG 412. In the test atmo-
sphere, the mass concentration of GNP particles ranged from
0.12 to 1.88 mg m−3, corresponding to daily deposited doses
of 0.6–9.9 μg per rat. Particles of the inhaled GNP were
observed in alveolar macrophages up to 90 days post-exposure,
with translocation also to lung lymph nodes. However, they
did not induce any lung pathology, inflammation, change
in blood biochemical parameters or genotoxic eﬀects at the
pulmonary level, evaluated using the comet assay. The
authors reported a No-Observed-Adverse-Eﬀect-Level (NOAEL)
>1.88 mg m−3.22
Minor signs of toxicity were recorded for GO: male Sprague-
Dawley rats (6 weeks-old) nose-only exposed for 6 h to GO
showed alveolar macrophages with ingested GO, also during
the recovery period of 14 days.23 These results are in line with
a very recent inhalation study in which male Sprague-Dawley
rats (6 weeks-old) were nose-only exposed for 5 days (6 h day−1)
to a GO having diﬀerent physicochemical properties (Table 2)
and monitored up to 21 days after exposure. The delivered
mass concentrations of GO ranged from 0.76 to 9.78 mg m−3,
corresponding to 3.25 × 103–9.97 × 103 particles per cm3. No
significant eﬀects were observed in the hematological analysis
or in the broncho-alveolar lavage fluid inflammatory markers
and cell number, both at the end of the exposure and during
the recovery period. However, alveolar macrophages with
ingested GO were observed, although a gradual clearance was
noted during the 21-day recovery period.24
Overall, the authors of three of five studies reported various
levels of lung inflammation in Wistar or Sprague-Dawley rats
after inhalation exposure to FLG, GNP or GO, not always revers-
ible at the last observation time (ranging from 14 to 90 days).
Although a NOAEL >1.88 mg m−3 of GNP was defined, based
Table 2 Physicochemical properties of GBMs evaluated in the in vivo studies after inhalation exposure (head-nose or only-nose exposure)
Lateral
size (nm)
Thickness
Surface area
Chemical
composition Impurity Density Aggregation
Test atmosphere
(µm) Ref.nm Layers
FLG <10 000 9 n/a 131 m2 g−1 C 84.1% 3D-graphite;
sulfur impurity
0.02 g mL−1 ∼40 µm, crumpled
napkin
MMAD≤0.4; particle
size = 0.473–0977
20
O 8.8%
S 5.4%
Na 0.6%
Si 0.4%
550 8 n/a 100 m2 g−1 C 76.8% n/a n/a n/a MMAD = 0.567;
particle size =
0.010–0.130
21
O 10.4%
Na 10.5%
P 2.4%
GO 10–120 n/a n/a n/a C 56.8% n/a 0.46–3.76 mg m−3 n/a Equivalent
hydrodynamic
diameter =
0.15–0.25
23
O 20.2%
K 11.3%
Na 8.3%
Cl 3.4%
500–5000 1 1–2 8.46 m2 g−1 C 42–45% n/a 1.7 g mL−1 Stacked platelet
structure
MMAD = 0.203;
particle size =
0.265–34
24
O 35–40%
GNP <2000 0.35–0.38 20–30 750 m2 g−1 C 96% n/a 0.2 g mL−1 n/a MMAD = 0.123;
particle size =
0.265–34
22
O 4%
n/a = data not available.
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on the lack of inflammation and other lung pathologies, blood
biochemical parameter changes and genotoxic eﬀects, the
presence of GNP in macrophages and in lung lymph nodes
was recorded up to 90 days after inhalation exposure.22
Furthermore, it has to be underlined that inhalation exposure
to GBMs was limited to 6 h or 1 week (5 days per week; 6 h
day−1) and only in one study it was extended to 4 weeks (5 days
per week; 6 h day−1), although the validated guidelines indi-
cate 4 weeks or 13 weeks of exposure (5 days per week; 6 h
day−1). No sub-chronic and chronic toxicity tests are available
to evaluate other toxic eﬀects and/or carcinogenicity, so far.
Oral exposure
Considering the exposure by ingestion, in vivo studies after
oral administration are limited to GO and rGO, whose physico-
chemical properties are reported in Table 3. Male Sprague-
Dawley rats (8–10 weeks-old) daily exposed by gavage to GO
(10–40 mg per kg per day) for 5 days showed dose-dependent
tissues signs of nephrotoxicity, tentatively mediated by oxi-
dative stress.25 In contrast, no alteration of kidney and liver
functions or hematochemical parameters was recorded in
male C57BL/6 mice (6–8 weeks-old) after daily oral exposure by
gavage, for 5 days, to 60 mg kg−1 of small or large sized rGO.
On evaluating the mouse behavior, only a short-term decrease
in locomotor activity and impaired neuromuscular coordi-
nation were initially observed, without eﬀects on anxiety-like,
exploratory, spatial learning and memory behaviors or tissue
changes in the hippocampus and neuroglia cells in the brain.
Moreover, after daily oral exposure by gavage, for 5 days, to
60 mg kg−1 of 125I-rGO, radioactivity was detected throughout
the whole body after one day from the last exposure: in des-
cending order in the kidney, stomach, liver, lung, and blood,
indicating a considerable absorption of rGO. The majority of
radioactivity decreased 15 or 60 days after the treatment.26
A perinatal study on GO (0.05 and 0.5 mg ml−1 in drinking
water, from day 1 to 21 after parturition) was carried out in
female ICR mice (age/weight not specified) during the lacta-
tion period to verify the developmental eﬀects on oﬀspring.
Significant perinatal toxic eﬀects were observed and ascribed
to the decreased maternal water consumption containing GO
during lactation and the reduced milk production.27
In conclusion, after 5-day repeated oral exposure to 125I-
rGO, the persistence of radioactivity significantly decreased
after 15 or 60 days. A significant absorption was recorded in
mice after 1 day from the last exposure, the kidney being the
most involved organ.26 These data seem to be in agreement
with the nephrotoxicity recorded in rats orally exposed to GO
for 5 days.25 A reduced milk production, tentatively consequent
to a decreased maternal mouse consumption of GO-containing
water, induced significant perinatal eﬀects. However, these
studies, limited to GO and rGO, provide insuﬃcient data for
the GBMs’ hazard identification and characterization associ-
ated with oral exposure.
Cutaneous exposure
Regarding cutaneous toxicity, except for few in vitro studies
showing the ability of FLG and GO to penetrate human
primary keratinocytes and to exert low cytotoxic eﬀects toward
human HaCaT keratinocytes and CRL-2522 fibroblasts,28–31 no
data are currently available on GBM eﬀects at the skin level,
one of the main barriers between the human body and the
environment.
The lack of these data hinders the characterization of
GBMs’ eﬀects at the skin level.
Ocular exposure
Concerning ocular toxicity, only two studies, limited to GO,
were carried out. An acute eye irritation test in New Zealand
white female rabbits (6 months-old), carried out according to
the OECD TG 405, showed that dripping of GO on the conjunc-
tival sac (10 μg per eye) did not cause local reactions. In con-
trast, after daily exposure of female Sprague-Dawley rats (3
weeks-old) to the same GO (25–200 ng per eye per day, for 5
days), reversible mild corneal opacity, conjunctival redness
and corneal epithelium damage were noted at 100 and 200 ng
per eye, which were mitigated by a topical treatment with
reduced glutathione as an antioxidant agent.32 Another study
in Japanese white rabbits (2–3 kg body weight, gender not
specified) showed that single intravitreal injection of GO
(100–300 ng per eye), which mimics a physical injury rather
than exposure by eye contact, induced negligible eﬀects on
eyeball appearance, intraocular pressure, eyesight and electro-
retinogram up to 49 days, when histological analysis revealed
no retinal alteration and a very small amount of residual GO.33
However, the physicochemical characterization of the tested
materials is incomplete (Table 4).
Table 3 Physicochemical properties of GBMs evaluated in the in vivo studies after oral exposure
Lateral size (nm)
Thickness
Surface area Chemical composition Impurity Density Aggregation Ref.nm Layers
GO 40 n/a n/a n/a n/a n/a n/a Agglomerated 25
200 1.8 2 n/a C/O ratio = 2.11 n/a n/a n/a 27
rGO 88 n/a n/a n/a n/a n/a n/a n/a 26
472 n/a n/a n/a n/a n/a n/a n/a
n/a = data not available.
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Although these findings indicate only minor ocular eﬀects,
they are not suﬃcient to draw any conclusion on GBMs’ eﬀects
at the ocular level.
Overall, some of these toxicity data suggest potential
adverse eﬀects for some materials, but general conclusions on
GBMs’ eﬀects cannot be drawn due to the limited solid avail-
able toxicity studies on laboratory animals. Consequently,
these toxicological data are not suﬃcient as a starting point
also to derive an occupational exposure limit (OEL) for GBMs
in working places. Further toxicological studies, tentatively
according to validated guidelines, have to be carried out to
identify and characterize the hazard posed by GBMs. These
studies should consider also other toxic eﬀects, including gen-
otoxicity and carcinogenicity as well as developmental and
reproductive toxicity. In fact, although Kim et al. did not
record genotoxic eﬀects in the lung tissues of rats repeatedly
exposed by inhalation to GNP (5 days, 6 h day−1),22 other in
vivo studies after diﬀerent exposure routes showed the geno-
toxic potential for some GBMs. In fact, El-Yamany et al.34
observed genotoxicity (DNA damage in the lung cells and chro-
mosomal aberrations in the bone marrow) in male albino
mice (strain not specified; 25 g) after the repeated intraperito-
neal injection of GO (10–500 μg kg−1, once a week, the number
of weeks not specified). A genotoxic eﬀect (micronucleated
polychromic erythrocytes) was also recorded after 5 days of
repeated intravenous injections of GO to Kunming mice
(25–30 g; gender not specified).35 Thus, the occurrence of gen-
otoxic eﬀects after long-term occupational exposure to GO or
other GBMs cannot be excluded.
Concerning the developmental and reproductive toxicity,
only two studies after oral and intratracheal exposure, respect-
ively, are available. Perinatal toxicity in oﬀspring after oral
daily exposure (day 1–21 post parturition) of lactating mice to
GO by drinking water (0.05 and 0.5 mg ml−1) was investigated,
recording a significant retardation of the body weight, body
length and tail length gain in the filial mice after exposure to
0.5 mg GO ml−1 (∼0.8 mg per mouse per day). Moreover, a
delayed development of oﬀspring and a decreased length of
the intestinal villi were recorded during the lactation period.
These eﬀects could be ascribed to the reduced milk production
due to the decreased GO-containing water consumption by
maternal mice.27 In contrast, no reproductive toxicity in male
mice was recorded after intratracheal instillation of GO, once a
week for 7 consecutive weeks (18 µg per mouse per instillation;
cumulative dose: 126 µg per mouse). No significant changes in
epididymal sperm parameters, daily sperm production or tes-
tosterone levels were found after GO exposure, suggesting no
reproductive toxicity in male mice.19
4. Occupational human exposure
Besides the potential hazard of GBMs, a crucial point of estab-
lishing OELs is the accurate and uniform evaluation of the
human exposure in working places. Very limited data are cur-
rently available on airborne GBM concentrations in occu-
pational settings, whose level depends on the production
method and the measures aimed to reduce the exposure. For
GNP, the airborne concentration during the collection of pro-
ducts from the discharge vessel was measured at 2.27 and
0.017 mg m−3.36 This concentration range is comparable to
that not inducing signs of toxicity after 5 days of repeated
nose-only exposure of rats to GNP (0.12–1.88 mg m−3)22 and
even lower than that of GO (0.76–9.78 mg m−3).24 Very recently,
experimental data, mimicking graphene production using
chemical vapor deposition (CVD) in a working place, demon-
strate no measurable risk of exposure to airborne graphene in
the studied site and only a transient increase in graphene pres-
ence during the cleaning of the reactors.16 In another study,
the exposure to graphene was monitored in two working places,
one using graphite exfoliation and CVD, and the other growing
graphene on a copper plate using CVD, which is then trans-
ferred to a polyethylene terephthalate sheet. The peak particle
number concentration was lower than 40 000 cm−3, with
elemental carbon concentrations mostly below the detection
limit, tentatively indicating a very low presence of graphene or
of any other particles and very limited exposure.37 In another
study, occupational exposure to GBMs by workers during the
large-scale production of graphene was assessed. After 8 h
average exposure, the particle concentration in air ranged from
909 to 6438 particles per cm3, equivalent to 0.38–3.86 μg cm−3.38
Comparable results were recently recorded for graphene within
a study proposing a multi-metric approach based on the harmo-
nized and tiered OECD methodology, in a research and develop-
ment laboratory.39 All these concentrations are far lower than
the inhalation exposure levels to GBMs provoking toxicity in
animals, as assessed by inhalation studies (see above).
5. Data gap identiﬁcation
During this literature survey, some gaps in knowledge to
assess the safety of GBMs for human health, ranging from
Table 4 Physicochemical properties of GBMs evaluated in the in vivo studies after ocular exposure
Lateral size (nm)
Thickness
Surface area Chemical composition Impurity Density Aggregation Ref.nm Layers
GO 120 <1.2 1 n/a n/a n/a n/a n/a 32
n/a 1 1 n/a n/a n/a n/a n/a 33
n/a = data not available.
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incomplete and not homogeneous physicochemical infor-
mation of the studied materials to the actual human exposure,
were identified.6 In particular, despite the use of standardized
preparation procedures, GBMs with diﬀerent physicochemical
properties (i.e. lateral size, surface area, shape, aggregation,
etc.) can be obtained. These diﬀerences are known to aﬀect the
toxicological properties of a GBM: for instance, the same
material can induce diﬀerent eﬀects if tested as dispersed par-
ticles or as agglomerates, aggregates or agglomerated aggre-
gates. Nevertheless, the physicochemical characterization of
the investigated GBM is not reported through standardized
parameters in all the toxicological studies (Tables 1–4).
Therefore, a correct comparison of the eﬀects recorded for the
same type of GBM is not always allowed. Furthermore, some
basic information on animals and experimental conditions,
which can impair the value of the in vivo toxicological results
(i.e. gender, age/weight, strain of animals, dark–light cycle,
environmental temperature, etc.), are missing in some studies. It
has to be underlined that besides the environmental conditions
of the animal house, which could provoke hormonal variations
aﬀecting a toxic response, also the intrinsic animal character-
istics (i.e. gender, strain, age, etc.) can aﬀect the toxic response.
These gaps can be overcome using validated guidelines for
nanomaterials, if available (i.e. OECD TG 412 and 413, for
inhalation exposure). Nevertheless, it has to be considered that
the results obtained following validated guidelines for chemi-
cals cannot always be directly applied to nanomaterials and,
consequently, the toxicological evaluation has to be extrapo-
lated with particular care.
Particular attention has to be paid to the exposure routes,
focusing on the most suitable animal models mimicking real-
life human exposure in occupational settings. For instance,
studies after respiratory exposure should be carried out using
head–nose or only-nose exposures models, avoiding non-phys-
iological routes (i.e. intratracheal instillation or pharyngeal
aspiration).
Further information on the Absorption, Distribution,
Metabolism and Excretion (ADME) is also needed. In fact, only
two animal studies on GBMs’ ADME related to occupational
exposure are available: they are limited to respiratory or oral
exposure to FLG, GNP or rGO.13,14,26 Other studies reporting
ADME data were carried out after exposure routes not associ-
ated with an occupational scenario. In particular, after
repeated intraperitoneal injection (8 injections in 4 weeks) in
female Wistar/cmdb outbred rats (6 weeks-old), GO (4 mg
kg−1) was accumulated as large agglomerates (up to 10 mm)
along the injection site, as medium dots (around 2 mm) along
the mesentery and as small dots (<1 µm) in the connective and
fatty tissues of the liver serosa.40 After an acute intravenous
injection of small or large 125I-GO (1 mg kg−1) in male ICR
mice (age/weight not specified), a diﬀerent distribution of the
two materials was observed: small GO mainly accumulated in
the liver, with few particles in the lungs and spleen, whereas
the lungs became the main storage depot for large GO.41
Considering genotoxicity, few contradictory studies in
rodents are reported: only one after respiratory exposure to
GNP22 and two by intravenous or intraperitoneal injection of
GO.34,35
Developmental toxicity should also be more deeply investi-
gated, considering that oral administration of GO to maternal
mice during lactation was shown to cause growth retardation
in oﬀspring.27 GO was shown to also induce malformations
in the embryos of the aquatic vertebrate zebrafish, an alterna-
tive model to assess developmental toxicity, incubated in a
medium containing GO at concentrations above 1 µg ml−1.42
Similarly, zebrafish embryos exposed to FLG (1–50 µg l−1) up
to 96 hours showed significant mortality, delayed hatching,
morphological defects, yolk sac edema and pericardial
edema.43 Moreover, a single intravenous injection of small
rGO or large rGO nanosheets (6.25 or 12.5 mg kg−1) to ICR
female mice (6–8 weeks-old) caused maternal death or abor-
tion during the late gestational stage,44 not giving any devel-
opmental toxicity indication due to the high administered
doses.
In addition, reproductive toxicity data after the usual occu-
pational exposure routes should be implemented, although no
adverse eﬀects were observed after repeated intratracheal
instillations (one exposure per week for 7 consecutive weeks)
of GO in NMRI male mice.19 Similarly, no reproductive adverse
eﬀects were observed in ICR male mice after single intravenous
(6.25–25 mg kg−1) or 5 days of intraperitoneal injection (up to
60 mg kg−1 day−1) of small GO or large GO.45 No eﬀects were
recorded after the intravenous injection of small rGO or large
rGO to ICR male and female 6–8 week-old mice (6.25–25.0 mg
kg−1).44 No histopathological changes were recorded in the
testes of BALB/c mice (6–8 weeks-old) after the intravenous
injection of GO (200 μg per mouse)46 or FLG (20 mg kg−1) to
Swiss albino mice (4–5 weeks-old).47 In contrast, the repeated
intraperitoneal injection of GO (0.4, 2.0 and 10.0 mg kg−1
day−1, 7 or 15 repeated doses on alternate days for 15 or 30
days) to male Wistar rats (10–12 weeks-old) resulted in some
adverse eﬀects on the sperms: oxidative stress in the testes
and, at the highest dose, also reduced sperm motility, total
sperm count, morphological sperm abnormalities and tissues
alterations in the testes. Anyway, structure and function altera-
tions in the testes showed a significant recovery within 30 days
of recovery period, while the fertility of male rats was not
aﬀected after the GO treatment.48 The physicochemical pro-
perties of the materials tested in these studies are reported in
Table 5.
Furthermore, more data should be acquired on the poss-
ible impact of GBMs on the immune system. In fact, GBM
accumulation in the macrophages and lung inflammation
frequently recorded in rodents after airway exposure to
these materials envisage an impact on the immune system.
Moreover, several in vitro studies showed significant eﬀects of
GBMs on immune cells.49–54 Thus, in vivo studies should be
carried out to elucidate the eﬀects of GBMs on the immune
system, also considering the use of these materials as bio-
medical tools.
Particular attention has to be paid to the potential carcino-
genic eﬀects of these materials, due to (i) their long persist-
Review Nanoscale
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ence in the animal body recorded in the available ADME
studies using radiolabeled materials;14,26,41 (ii) the inflamma-
tory/fibrotic eﬀects, observed in the lungs after acute intratra-
cheal instillation or 5 days of repeated inhalation exposure,
and the deposition in the lung macrophages, which appeared
to be not reversible within 14/90 days recovery.11,13,14,20–24 On
the basis of the current available data, carcinogenic eﬀects
induced by GBMs cannot be excluded, considering that related
materials (some types of multiwalled carbon nanotubes) are
classified by the International Agency for Research on Cancer
(IARC) within the 2B group (possibly carcinogenic to humans).
However, it should be clear that long, aggregated multiwalled
carbon nanotubes have a completely diﬀerent shape as well as
mechanical properties, in comparison with graphene. Thus,
considering the potential future market of GBMs, information
on the potential carcinogenicity of these materials should be
gathered for proper risk management to protect human health
and environment, in compliance with specific regulations,
such as the REACH (Registration, Evaluation, Authorisation
and restriction of Chemicals) in the European Union. Sub-
chronic and chronic studies following validated guidelines,
suitable for regulatory purposes, are also necessary for the
hazard identification and characterization of GBMs.
More data are also required for the occupational exposure
assessment of GBMs through environmental monitoring
studies carried out at the breathing area of the workers as well
as by cutaneous dosimetry on the workers’ skin or clothes.
Moreover, it has to be kept in mind that the exposure can be
complex, involving more than one exposure route. Further
exposure monitoring data should include the measurement of
GBMs and/or toxicity biomarkers in workers exposed to these
materials, until other human data (i.e. case reports, epidemio-
logical studies etc.) are not available.55
All this information is important to define the OELs for
GBMs, which could be further adjusted when workers health
surveillance and/or other human data will be available.
6. Conclusions
The risk to human health posed by GBMs is associated mainly
with an occupational scenario, during their industrial or
small-scale production and waste discharge, which can occur
mainly by inhalation, ingestion, cutaneous and ocular
exposure. The inhalation toxicity data in laboratory animals,
especially those obtained by toxicological studies, partially fol-
lowing the OECD guidelines, suggest that acute, 5 days and/or
4 weeks of repeated inhalation exposure to the tested GBMs
(FLG, GO and GNP) might induce lung inflammatory/fibrotic
reactions. However, these data are not suﬃcient to determine
OELs since the relevant studies have been limited to a
maximum of 5 days or 4 weeks of repeated exposure, so far.
Anyway, based on the available data, airborne levels of GBMs
in occupational settings seem to be lower than those inducing
signs of toxicity in animal studies. Nevertheless, it is note-
worthy that chronic and/or carcinogenicity studies are not yet
available.
On the other hand, no conclusions can be drawn for the
oral, cutaneous and ocular exposure for which very scanty
data, limited to GO or rGO are available, so far.
Thus, more data for the hazard identification and charac-
terization should be acquired by robust sub-chronic and
chronic toxicological studies, following the oﬃcial guidelines
for regulatory purposes. If available, validated guidelines
specific for nanomaterials have to be used, since those vali-
dated for chemicals cannot always be applied to nano-
Table 5 Physicochemical properties of GBMs evaluated in the in vivo studies after other exposure routes
Lateral
size (nm)
Thickness
Surface area
Chemical
composition Impurity Density Aggregation
In vivo
exposure
route Ref.nm Layers
FLG 160 0.8 2–4 n/a n/a n/a n/a n/a iv 47
GO 8–25 n/a n/a 540–650 m2 g−1 n/a n/a n/a n/a ip 40
100–500 0.9 1 n/a n/a n/a n/a n/a iv 41
1000–5000 n/a n/a n/a n/a n/a
156.4 0.7–1.5 1–2 n/a n/a n/a n/a n/a iv 35
300–1000 1 n/a n/a n/a n/a n/a Stablea iv 46
55 <4 n/a n/a n/a n/a n/a n/a iv/ip 45
238 n/a n/a n/a n/a n/a n/a
n/a n/a n/a n/a n/a n/a n/a n/a ip 34
5000–10 000 0.8–2 3–6 >350 m2 g−1 C 77.5% n/a 0.121 g mL−1 n/a ip 48
O 16.0%
S 0.4%
H 1.2%
N 4.9%
rGO 68 n/a 1–5 n/a n/a n/a n/a n/a iv 44
659 n/a n/a n/a n/a n/a n/a
iv = intravenous exposure; ip = intraperitoneal exposure. n/a = data not available. a The authors report that the GO suspension was stable for at
least 1 month at room temperature.
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materials: in this case, the toxicological evaluation has to be
extrapolated with particular care. In parallel, environmental
monitoring to assess the actual occupational exposure to
GBMs should be carried out in working places, in association
with workers’ health surveillance. Once occupational exposure
to GBMs and their impact on human health are clarified, we
believe that identification of high-quality and safe GBMs, pro-
duced by the optimized standard procedures, will provide
benefits to diﬀerent industrial sectors and healthcare fields, in
compliance with defined regulations, thus improving the poss-
ible negative public perception on nanotechnology.
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